NCT02497508View on ClinicalTrials.gov

Nivolumab in Patients With Recurrent Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Malignant Pleural Mesothelioma
Interventions
DRUG

nivolumab

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER